Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 10/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24974740 | 0.94 | NAMPT (0.49) | NAMPTLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24974640 | 0.89 | NAMPT (0.54) | NAMPTLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24974750 | 0.86 | NAMPT (0.44) | NAMPTSNCASMN1; SMN2 | |
| SCHEMBL24974388 | 0.82 | NAMPT (0.41) | NAMPTLMNASNCASMN1; SMN2 | |
| SCHEMBL24974738 | 0.81 | L3MBTL1 (0.38) | NAMPTMEN1KMT2AHDAC1HDAC2 | |
| SCHEMBL21122085 | 0.80 | PKM (0.47) | — | |
| SCHEMBL24974467 | 0.77 | NAMPT (0.42) | NAMPTLMNASNCASMN1; SMN2 | |
| SCHEMBL21151298 | 0.72 | LMNA (0.53) | LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16271204 | 0.69 | MEN1 (0.54) | NAMPTMEN1KMT2AHDAC1HDAC2 | |
| SCHEMBL3697534 | 0.69 | NAMPT (1.00) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | NAMPT 1356/4885LMNA 2855/4885SNCA 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.